Back to Journals » International Journal of Women's Health » Volume 8

Profile of olaparib in the treatment of advanced ovarian cancer

Authors Chase D, Patel S, Shields K

Received 29 September 2015

Accepted for publication 1 December 2015

Published 18 April 2016 Volume 2016:8 Pages 125—129


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Fredrick Rosario Joseph

Peer reviewer comments 2

Editor who approved publication: Professor Elie Al-Chaer

Dana M Chase,1,2 Shreya Patel,2,3 Kristin Shields4

1Division of Gynecologic Oncology, The University of Arizona Cancer Center, 2Division of Gynecologic Oncology, 3Creighton University School of Medicine, St Joseph’s Hospital and Medical Center, Phoenix, AZ, 4Department of Trauma, Critical Care, and Acute Care Surgery, Medical College of Wisconsin, Milwaukee, WI, USA

Abstract: Olaparib is a poly(ADP-ribose) polymerase inhibitor that received accelerated approval from the US Food and Drug Administration as monotherapy for patients with germline BRCA mutations and ovarian cancer treated with three or more prior lines of chemotherapy. This article summarizes the mechanism of poly(ADP-ribose) polymerase inhibition, therapeutic profile and uses of olaparib, and current and ongoing literature pertaining to olaparib in advanced ovarian cancer.

Keywords: olaparib, PARP, ovarian cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]